Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer

Amino Acids

Volumn 44, Issue 2, 2013, Pages 543-553

  Yu, Zilin ^a   Carlucci, Giuseppe ^a   Ananias, Hildo J K ^a   Dierckx, Rudi A J O ^a   Liu, Shuang ^b   Helfrich, Wijnand ^a   Wang, Fan ^c   De Jong, Igle J ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PURDUE UNIVERSITY   (United States)

^c PEKING UNIVERSITY   (China)

Author keywords

99mTc; Bombesin homodimer; GRPR; HYNIC; Imaging; PC 3; Prostate cancer; Radiolabeled; SPECT

Indexed keywords

BOMBESIN; BOMBESIN 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID CONJUGATE; CARBOXYLIC ACID; DIAGNOSTIC AGENT; EPSILON AMINOCAPROIC ACID BOMBESIN[7-15]; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUTAMIC ACID (EPSILON AMINOCAPROIC ACID BOMBESIN[7-15])(EPSILON AMINOCAPROIC ACID BOMBESIN[7-15]); HOMODIMER; IODINE TYROSINE BOMBESIN[1-14]I 125; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID (TRICINE TRISODIUM TRIPHENYLPHOSPHINE 3,3',3'' TRISULFONATE)EPSILON AMINOCAPROIC ACID BOMBESIN[7-15]TC 99M; TECHNETIUM 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID (TRICINE TRISODIUM TRIPHENYLPHOSPHINE 3,3',3'' TRISULFONATE)GLUTAMIC ACID (EPSILON AMINOCAPROIC ACID BOMBESIN[7-15])(EPSILON AMINOCAPROIC ACID BOMBESIN[7-15])TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; DIMERIZATION; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSPORT KINETICS;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; DIMERIZATION; HUMANS; ISOTOPE LABELING; KINETICS; MALE; MICE; MICE, NUDE; MOLECULAR IMAGING; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, BOMBESIN; TECHNETIUM;

MUS; MUS MUSCULUS;

EID: 84878376632     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-012-1369-9     Document Type: Article

References (33)

1. Ait-Mohand S, Fournier P, Dumulon-Perreault V, Kiefer GE, Jurek P, Ferreira CL, Benard F, Guerin B (2011) Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem 22(8):1729-1735. doi: 10.1021/bc2002665
2. Ananias HJ, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, Yan Y, Chen X, de Jong IJ, Elsinga PH (2011) (99m)technetium-HYNIC(tricine/TPPTS)-Aca- bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm 8(4):1165-1173. doi: 10.1021/mp200014h
3. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE (1993) Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71(12):3952-3965
4. Chang E, Liu S, Gowrishankar G, Yaghoubi S, Wedgeworth JP, Chin F, Berndorff D, Gekeler V, Gambhir SS, Cheng Z (2011) Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging 38(4):722-730. doi: 10.1007/s00259-010-1672-1
5. Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, Oyen WJ, Corstens FH, Liskamp RM, Boerman OC (2007) Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 34(2):267-273. doi: 10.1007/s00259-006-0180-9
6. Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, Oyen WJ, Boerman OC (2011) PET imaging of alphavbeta integrin expression in tumours with Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 38(1):128-137. doi: 10.1007/s00259-010-1615-x
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
8. Erspamer V, Erpamer GF, Inselvini M (1970) Some pharmacological actions of alytesin and bombesin. J Pharm Pharmacol 22(11):875-876
9. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581-592. doi: 10.1093/annonc/mdl498
10. Handl HL, Vagner J, Yamamura HI, Hruby VJ, Gillies RJ (2004) Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem 330(2):242-250. doi: 10.1016/j.ab.2004.04.012
11. Harris TD, Sworin M, Williams N, Rajopadhye M, Damphousse PR, Glowacka D, Poirier MJ, Yu K (1999) Synthesis of stable hydrazones of a hydrazinonicotinyl-modified peptide for the preparation of 99m Tc-labeled radiopharmaceuticals. Bioconjug Chem 10(5):808-814 pii:bc9900237
12. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673-687 pii: S0092867402009716
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics. CA Cancer J Clin 58(2):71-96. doi: 10.3322/CA.2007.0010
14. Joosten JA, Loimaranta V, Appeldoorn CC, Haataja S, El Maate FA, Liskamp RM, Finne J, Pieters RJ (2004) Inhibition of Streptococcus suis adhesion by dendritic galabiose compounds at low nanomolar concentration. J Med Chem 47(26):6499-6508. doi: 10.1021/jm049476+
15. Kramer RH, Karpen JW (1998) Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 395(6703):710-713. doi: 10.1038/27227
16. Li ZB, Wu Z, Chen K, Ryu EK, Chen X (2008) 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 49(3):453-461. doi: 10.2967/jnumed.107.048009
17. Liu S, Kim YS, Hsieh WY, Gupta Sreerama S (2008) Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. Nucl Med Biol 35(1):111-121. doi: 10.1016/j.nucmedbio.2007.08. 006
18. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X (2009a) Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 50(7):1168-1177. doi: 10.2967/jnumed.108.061739
19. Liu Z, Niu G, Wang F, Chen X (2009b) (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 36(9):1483-1494. doi: 10.1007/s00259-009-1123-z
20. Liu Z, Yan Y, Chin FT, Wang F, Chen X (2009c) Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 52(2):425-432. doi: 10.1021/jm801285t
21. Liu Z, Yan Y, Liu S, Wang F, Chen X (2009d) (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 20(5):1016-1025. doi: 10.1021/bc9000245
22. Liu Z, Shi J, Jia B, Yu Z, Liu Y, Zhao H, Li F, Tian J, Chen X, Liu S, Wang F (2011) Two Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol Pharm 8(2):591-599. doi: 10.1021/mp100403y
23. McDonald TJ, Jornvall H, Nilsson G, Vagne M, Ghatei M, Bloom SR, Mutt V (1979) Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun 90(1):227-233 pii:0006-291X(79)91614- 0
24. Mulder A, Huskens J, Reinhoudt DN (2004) Multivalency in supramolecular chemistry and nanofabrication. Org Biomol Chem 2(23):3409-3424. doi: 10.1039/b413971b
25. Price J, Penman E, Wass JA, Rees LH (1984) Bombesin-like immunoreactivity in human gastrointestinal tract. Regul Pept 9(1-2):1-10
26. Schroeder RP, Muller C, Reneman S, Melis ML, Breeman WA, de Blois E, Bangma CH, Krenning EP, van Weerden WM, de Jong M (2010) A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 37(7):1386-1396. doi: 10.1007/s00259-010- 1388-2
27. Shi J, Jia B, Liu Z, Yang Z, Yu Z, Chen K, Chen X, Liu S, Wang F (2008) 99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem 19(6):1170-1178. doi: 10.1021/bc700471z
28. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S (2009) Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 20(4):750-759. doi: 10.1021/bc800455p
29. Spindel ER, Chin WW, Price J, Rees LH, Besser GM, Habener JF (1984) Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci USA 81(18):5699-5703
30. Track NS, Cutz E (1982) Bombesin-like immunoreactivity in developing human lung. Life Sci 30(18):1553-1556
31. Vance D, Shah M, Joshi A, Kane RS (2008) Polyvalency: a promising strategy for drug design. Biotechnol Bioeng 101(3):429-434. doi: 10.1002/bit.22056
32. Xiao D, Wang J, Hampton LL, Weber HC (2001) The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene 264(1):95-103. doi: 10.1016/S0378-1119(00)00596-5
33. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X (2006) 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47(3):492-501